efficacy and efficiency," said John Milligan, Gilead's President and chief executive officer. "We believe Sangamo's zinc finger nucleases provide the optimal gene-editing platform, and we look ...

After years of demands from shareholders for another major deal, Gilead has made a spectacular move, sealing a deal to acquire cell therapy leader Kite for just under $12 billion. Gilead had been ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

The gospel of John is dramatically different than the synoptic gospels (Matthew, Mark and Luke). Instead of organizing historical events into a chronology, John presents Jesus in all of his ...

After hours: February 7 at 7:58:40 PM EST ...

After hours: February 7 at 7:58:40 PM EST Loading Chart for GILD ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...